Day One Announces New FIREFLY-1 Data for Tovorafenib

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to...

Related Keywords

United States ,Canada ,Brisbane ,Queensland ,Australia ,California ,American ,Lindsay Kilburn ,Jeremy Bender ,Laura Cooper ,Samuel Blackman ,European Commission ,Children National Medical Center ,Company On Linkedin Or Twitter ,Head Of Communications ,Drug Administration ,American Society Of Clinical Oncology ,Oncology Consortium ,Exchange Commission ,One Biopharmaceuticals ,Clinical Oncology ,New Drug Application ,Day One ,Response Assessment ,Neuro Oncology High Grade Glioma ,Pediatric Neuro Oncology Low Grade Glioma ,National Medical ,Exploratory Endpoint ,Independent Review Committee ,Pacific Pediatric Neuro Oncology Consortium ,Pacific Pediatric Neuro Oncology ,Breakthrough Therapy ,Rare Pediatric Disease ,Orphan Drug ,Private Securities Litigation Reform Act ,Nasdaq Dawn ,Day One Biopharmaceuticals ,Nc ,